Armata wins FDA Breakthrough Therapy designation for AP-SA02
Armata Pharmaceuticals said the FDA granted Breakthrough Therapy designation for AP-SA02, supported by Phase 1b/2a data showing higher and earlier clinical cure rates versus placebo plus antibiotics. The company plans Phase 3 in the second half of 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.